Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction
Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction
复制标题
DOI：
10.1002/ijc.32784
复制
发表时间：
2019-12-04
影响因子：
6.4
通讯作者：
Yerly, S.
中科院分区：
文献类型：
--
作者：
Combes, Jean-Damien;Clifford, Gary M.;Yerly, S.
我们的目的是描述HPV 16 E6抗体动力学与艾滋病毒/艾滋病（PLWHA）的人肛门癌之前，并评估HPV 16 E6血清学的肛门癌风险预测的可能贡献。在瑞士HIV队列研究（1989-2017）中，对91名被诊断患有肛门癌的人，使用多重血清学检测了一系列血清/血浆样本中的HPV 16 E6抗体，并补充了来自1，356名无肛门癌参与者的样本。肛门癌的发病率估计从40岁的cART时代，分层的HPV 16 E6血清状态。10年样本中HPV 16 E6血清阳性率为23.3%。在随访期间的任何时间HPV 16 E6血清阳性的25名肛门癌患者中，大多数（n = 18）在血清转换后的所有样本中保持血清阳性，而7例血清阳性是暂时的。在肛门癌患者中，女性HPV 16 E6血清阳性率略高于男男性行为者（调整后OR = 4.3，95% CI：1.1，17.2）和老年参与者（调整后OR = 6.2，95% CI：1.1，34.8，诊断年龄≥ 55岁的病例与男性发生性关系的病例相比）。
Our aim was to describe HPV16E6 antibody kinetics prior to anal cancer in people living with HIV/AIDS (PLWHA) and evaluate the possible contribution of HPV16E6 serology to anal cancer risk prediction. For 91 persons diagnosed with anal cancer in the Swiss HIV Cohort Study (1989-2017), serial serum/plasma samples were tested for HPV16E6 antibodies using multiplex serology, supplemented with samples from 1,356 participants without anal cancer. Anal cancer incidence was estimated for PLWHA from 40 years-old in the cART era, stratified by HPV16E6 serostatus. HPV16E6 seroprevalence was 23.3% in samples = 10 years. Of 25 individuals with anal cancer who were HPV16E6-seropositive at any time during follow-up, the majority (n = 18) remained seropositive in all samples after seroconversion, whereas for seven cases, seropositivity was transitory. Among individuals with anal cancer, HPV16E6 seroprevalence was marginally higher in women vs. men who have sex with men (adjusted OR = 4.3, 95% CI: 1.1, 17.2) and in older participants (adjusted OR = 6.2, 95% CI: 1.1, 34.8 for cases diagnosed at >= 55 vs.